Background. Hyperuricemia has been linked to cardiovascular and renal diseases, possibly through the generation of reactive oxygen species (ROS) and subsequent endothelial dysfunction. The enzymatic effect of xanthine oxidase is the production of ROS and uric acid. Studies have shown that inhibiting xanthine oxidase with allopurinol can reverse endothelial dysfunction. Furthermore, rat studies have shown that hyperuricemiainduced hypertension and vascular disease is at least partially reversed by the supplementation of the nitric oxide synthase (NOS) substrate, L-arginine. Therefore, we hypothesized that uric acid induces endothelial dysfunction by inhibiting nitric oxide production.
Endothelial dysfunction, particularly impaired nitric oxide production, is a common finding in patients with cardiovascular and renal diseases and is thought to be mediated in part by reactive oxygen species (ROS) [1] . ROS can be generated by several mechanisms, one of which involves reaction of xanthine oxidase with xanthine to generate superoxide anion and uric acid. Several studies have reported that xanthine oxidase inhibitors such as allopurinol can reverse endothelial dysfunction in subjects with congestive heart failure [2, 3] or type 2 diabetes mellitus [4] . These latter studies assume that the benefit of xanthine oxidase inhibition was solely via its ability to lower ROS; however, xanthine oxidase inhibitors also lower uric acid. Indeed, there is also strong evidence linking uric acid with cardiovascular and renal disease [5] . Specifically, animals made hyperuricemic by administering an inhibitor of uricase (which happens to also block oxidant formation) develop hypertension and vascular disease, which is at least partially reversed by supplementing with L-arginine, a nitric oxide synthase (NOS) substrate [6] . A study in healthy volunteers has also shown that serum uric acid inversely fluctuates with the potent vasodilator nitric oxide during a 24-hour period [7] . Given these findings, we hypothesized that hyperuricemia may induce endothelial dysfunction by inhibiting the production of nitric oxide.
METHODS

In vivo studies
Male Sprague-Dawley rats were housed in standard conditions and fed normal diets. We induced hyperuricemia with an uricase inhibitor, oxonic acid (750 mg/ kg/day), by gavage, with control rats receiving vehicle. Allopurinol was used to block hyperuricemia by placing allopurinol in the drinking water (150 mg/L). Rats were divided into four groups: (1) control, (2) allopurinol only, (3) oxonic acid only, and (4) oxonic acid + allopurinol. Systolic blood pressure was measured using a tail-cuff sphygmomanometer. The amount of drinking water consumed and changes in body weight were noted. Rats were sacrificed at 1 and 7 days. Serum was analyzed for uric acid concentration and nitrites/nitrates (NO X ) by chemiluminescence method [8] . Statistical analysis between subgroups was performed using analysis of variance (ANOVA).
In vitro studies
Bovine aortic endothelial cells (BAEC) (passages 4 to 8) (Cambrex, East Rutherford, NJ, USA) were cultured in endothelial growth media (EBM) with Bullet Kit (Cambrex). The effect of soluble uric acid (2.5 to 7.5 mg/dL) on nitric oxide production was measured in real-time based on the fluorescence of 4,5-diaminofluorescein (DAF-2) which binds to nitric oxide [9] . Specifically, control BAEC and BAEC treated with different concentrations of uric acid (2.5 to 7.5 mg/dL for 24 hours) were first washed in Hank's balanced salt solution (HBSS) and then incubated with 5 lmol/L DAF-FM diacetate (Molecular Probes, Eugene, OR, USA) for 30 minutes at 37
• C in darkness. After the incubation, BAEC were washed to remove excess probe. Fresh HBSS containing 100 lmol/L L-arginine (a substrate for nitric oxide synthesis) was added to cells, and cells were incubated for an additional 10 minutes to allow complete de-esterification of the intracellular diacetate. After this procedure, direct visualization of nitric oxide production with the fluorescent indicator was performed using a laser scanning confocal microscope with excitation and emission maxima at 495 and 515 nm, respectively. Intensity of fluorescence was quantified using LSM 510 (version 3.0 SP3) software for the Carl Zeiss Laser Scanning Microscope (Carl Zeiss, Inc.). The amount of nitric oxide released into the cell media was also measured in the gas phase using a standardized Seivers NOA 280 chemiluminescence analyzer (Analytix, Durham, UK), after cells were stimulated with vascular endothelial growth factor (VEGF 165 ) (50 ng/mL) in EBM with 5% serum for 24 hours. Results are corrected for background levels of nitric oxide present in culture medium alone, and are expressed as nanomol per microgram (nitric oxide/total protein) and as a mean ± SEM of three independent experiments performed in triplicate determinations.
RESULTS
There was no difference in the amount of water consumed and the change in body weight between the three groups over seven days. Oxonic acid induced a mild hyperuricemia at both 1 day (1.7 ± 0.7 vs. 0.8 ± 0.4 mg/dL in oxonic acid vs. control) (P < 0.05) and 7 days (1.8 ± 0.4 vs. 0.9 ± 0.7 mg/dL in oxonic acid vs. control) (P < 0.05). Allopurinol only had a mild and nonsignificant effect on serum uric acid concentrations at day 1 (1.52 ± 0.3 mg/dL) (P = NS), but effectively reversed the hyperuricemia at 7 days (0.3 ± 0.2 mg/dL) (P < 0.001). Serum nitrites and nitrates (NO X ) were reduced by 40% to 50% in hyperuricemic rats at both 1 day (15.6 ± 0.4 vs. 22.6 ± 1.0 lmol/L in oxonic acid vs. control) (P < .001) and 7 days (14.6 ± 1.1 vs. 27.5 ± 1.3 lmol/L in oxonic acid vs. control) (P < .001). This decrease in NO X was improved slightly by allpurinol at 1 day (17.4 ± 0.8 lmol/L) (P < .001) and reversed completely at 7 days (25.0 ± 0.8 lmol/L) (P < 0.001) (Fig. 1) . There was also a direct linear correlation between serum uric acid and NO X (Fig. 2) . Rats treated with allopurinol alone did not show a significant change in either serum uric acid or NO X concentration. Rats treated with oxonic acid also showed a trend toward higher systolic blood pressure at 7 days (178 ± 18 vs. 158 ± 16 vs. 147 ± 11 mm Hg in oxonic acid vs. control vs. oxonic acid/allopurinol) (P = NS).
Additional studies were performed to determine if uric acid affected nitric oxide production in cultured endothelial cells. Uric acid dose-dependently inhibited nitric oxide production ( Fig. 3A and B) as measured by DAF-FM fluorescence; uric acid (5 mg/dL) also blocked VEGF-induced nitric oxide release into the culture media (Fig. 3C) .
CONCLUSION
Most mammals have the enzyme uricase that degrades uric acid to allantoin with the generation of oxidants. In humans, uricase is mutated resulting in higher uric acid levels. Rats administered an uricase inhibitor (oxonic acid) develop mild hyperuricemia, hypertension, and vascular disease that is mediated by activation of the reninangiotensin system, a loss of macula densa NOS, and the development of microvascular disease [6] . In this study we also demonstrate that hyperuricemic rats have a fall in serum nitrites (a reflection of nitric oxide production) that is reversed by allopurinol. Furthermore, there was a direct linear correlation between serum uric acid and serum nitric oxide. The induction of hyperuricemia also showed a trend toward increased systolic blood pressure. In addition, we found that uric acid also impaired both basal and VEGF-induced nitric oxide production in cultured endothelial cells. This data suggest that hyperuricemia may cause endothelial dysfunction. Interestingly, Waring et al [10] recently reported that the infusion of uric acid into humans does not impair endothelial function over a 1-hour period. However, these studies did not measure nitric oxide levels nor mention effects of sustained hyperuricemia on endothelial-dependent vasodilatation. These discrepancies can also be explained by differences in methods and species, suggesting the need for further studies to dissect out the complex relationship of uric acid to endothelial function and cardiovascular disease.
